U.S. Markets close in 5 mins

Rite Aid's January Comps Climb

Zacks Equity Research

Drugstore chain retailer, Rite Aid Corporation’s (RAD) same-store sales (comps) for the four weeks ended Jan 26, 2013 inched up 0.3%. The rise was an outcome of an increase in front-end comps, offset by a decline in pharmacy comps.

Higher over-the-counter sales of flu-related products resulted in a 4.2% rise in the company’s front-end comps. Flu-related product sales contributed 2.4% to the growth in front-end comps. Despite a 5.0% increase in prescription counts at comparable stores, Pharmacy comps for January declined 1.4%. Pharmacy comps for the month was adversely impacted by about 665 basis points due to the introduction of new generic drugs. An increase of 3.4% in flu-related prescriptions and flu shots primarily prompted the growth in prescription counts.

Rite Aid reported total drugstore sales of $1.914 billion for the month, with prescription sales accounting for 68.9% of drugstore sales and third-party prescription sales making up for 96.2% of pharmacy sales. The company’s January sales declined 0.5% from the year-ago level of $1.923 billion.

Year-to-date, i.e. for the 47-week period ended on Jan 26, the company’s comps were up by a modest 0.1%, while net sales slipped 0.6% year over year to $22.826 billion. The increase in comps mainly came from a 1.6% rise in front-end comps partially offset by a 0.7% decrease in pharmacy comps. Meanwhile, prescription count at comparable stores jumped 3.7%.

Prescription sales comprised 67.5% of total drugstore sales. Additionally, third-party prescription sales accounted for 96.5% of pharmacy sales.

Our Recommendation

Rising estimates over the last 60 days – basically due to the company’s solid third-quarter fiscal 2013 results and revised bottom-line outlook – have helped Rite Aid to achieve a Zacks Rank #1 (Strong Buy).

Other drug store stocks that are performing well include CVS Caremark Corporation (CVS), AmerisourceBergen Corporation (ABC) and Cardinal Health Inc. (CAH). These companies currently have a Zacks Rank #2 (Buy).

Read the Full Research Report on RAD

Read the Full Research Report on CAH

Read the Full Research Report on ABC

Read the Full Research Report on CVS

Zacks Investment Research

More From Zacks.com